# Phase II/III Seamless Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Treatment of Seasonal Allergic Rhinitis

> **NCT06846385** · PHASE2,PHASE3 · RECRUITING · sponsor: **Shanghai Mabgeek Biotech.Co.Ltd** · enrollment: 160 (estimated)

## Conditions studied

- Seasonal Allergic Rhinitis

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** MG-K10 Humanized Monoclonal Antibody Injection

## Key facts

- **NCT ID:** NCT06846385
- **Lead sponsor:** Shanghai Mabgeek Biotech.Co.Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-20
- **Primary completion:** 2025-05-31
- **Final completion:** 2025-09-30
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2025-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06846385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06846385, "Phase II/III Seamless Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Treatment of Seasonal Allergic Rhinitis". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06846385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*